The restart nobody plans for

An interruption in this class is not simply a pause. Because plasma concentrations decline with a half-life of roughly a week for the long-acting agonists, four weeks without a dose leaves something on the order of six per cent of steady-state exposure in circulation. Tolerability adaptations that took two months to establish substantially unwind over that period. A person resuming at their previous dose is therefore not continuing treatment; they are starting a new escalation at a rung they have not occupied for a month, and the symptom response is often indistinguishable from a first exposure.

The arithmetic of a step

A dose increase should be described as a ratio, because receptor occupancy and the exposure-response relationship are governed by proportional change rather than by absolute milligrams. On the semaglutide weight-management ladder the ratios are 2.00, 2.00, 1.70 and 1.41. On the tirzepatide ladder they are 2.00, 1.50, 1.33, 1.25 and 1.20.

Two consequences follow. The first is that the early rungs are the hard ones, in both ladders, and the widespread expectation that titration gets progressively more difficult is backwards. The second is that a person who has tolerated the doubling at the bottom of the ladder has already survived the largest proportional insult the schedule contains.

There is a third, less obvious consequence for anyone dosing from a multi-dose vial rather than a fixed pen. Fixed-pen users move in the ratios above. Vial users can move in any ratio they like, including ratios small enough to be pharmacologically meaningless and large enough to be foolish. Freedom of increment is the single largest practical difference between pen and vial administration, and the arithmetic is the only guardrail.

Accelerated and decelerated schedules

The evidence on deviating from four-week steps is observational and one-sided. Slower escalation — five, six or eight weeks per rung — is reported by clinicians to reduce early discontinuation, is consistent with the tachyphylaxis data, and has never been randomised against the standard interval in a trial of adequate size. Faster escalation has no supporting rationale we can identify and a clear kinetic argument against it.

What can be said with confidence is that the cost of going slower is bounded and calculable: a longer time to target exposure, and therefore a later arrival at the efficacy plateau. Because the plateau itself sits at sixty weeks or beyond, adding four or eight weeks to the escalation phase is a small fraction of the treatment course. The cost of going faster is a higher probability of discontinuation, and discontinuation costs the entire effect.

That asymmetry is the strongest thing the Journal is willing to say on the subject. It is an argument from consequence rather than from trial data, and we flag it as such rather than dressing it as a finding.¹

What the withdrawal designs established

Two trials in this class were built specifically to answer what happens when treatment stops. In the semaglutide programme, participants who had escalated to the top dose over twenty weeks were then randomised to continue or to switch to placebo; those continuing lost a further eight per cent of body weight over the following forty-eight weeks while those withdrawn regained about seven per cent.² In the tirzepatide programme, a thirty-six-week open-label lead-in was followed by randomised continuation or withdrawal, with the continuation group losing a further five and a half per cent and the withdrawal group regaining approximately fourteen per cent.³

These are among the most informative results in the field and they are frequently over-read. What they establish is that the effect is maintained by continued exposure and reverses without it. What they do not establish, because neither design examined it, is whether a reduced maintenance dose would hold the result. The comparison was full dose against nothing.

Given that cost is the leading reported reason for stopping, a randomised comparison of full-dose against half-dose maintenance would be one of the highest-value trials nobody has run.

A gap, quantified

Residual exposure after an interruption follows from the half-life alone. For a seven-day half-life at steady state, one missed week leaves about half of accumulated concentration at the point the next dose was due, two weeks about a quarter, three weeks about an eighth, four weeks roughly six per cent, and six weeks under two per cent.

That table does most of the practical work. A single omission is a minor perturbation and the labels reflect this, generally permitting the dose to be taken within a defined window and otherwise skipped, with an explicit instruction not to double up. A gap of a fortnight leaves enough drug that resumption at the previous dose is usually uneventful. A gap of a month or more is functionally a fresh start.

The Journal notes that the labels handle the first case clearly and the third case briefly, and that the second case — the two-to-three-week gap that supply problems produce most often — is where guidance is thinnest and where the numbers above are most useful.⁴

Re-titration in practice

The convention after a long interruption is to resume one or two rungs below the previous dose and re-escalate on the standard interval. Clinicians described re-escalation as generally faster than the original ascent, on the grounds that a person who previously tolerated a rung is likely to tolerate it again, but there is no trial evidence for accelerated re-titration and the kinetic argument for four-week steps applies unchanged.

Two failure modes recur. The first is resuming at the previous top dose because that was the dose on the last prescription, which reproduces first-exposure symptoms in someone who has forgotten what they were like. The second is the opposite: restarting at the initiation dose after a two-week gap, which discards several weeks of adaptation for no reason.

Both are avoidable with the residual-exposure figures and a note of the date of the last injection. The Journal has come to regard that date as the single most useful piece of information a person on this treatment can keep, and the one most reliably absent when it is needed.

Supply interruption as a dosing event

In this market, gaps are usually structural rather than personal. Shortage listings, restrictions on compounded supply, price movements, customs interdiction and vendors ceasing to trade all produce interruptions that arrive without notice and end without warning. We have documented gaps of one to eleven weeks arising purely from supply, in people who missed no dose voluntarily.

The practical consequence is that anyone dependent on a single source is also dependent on that source for the continuity of their titration. Several people described re-escalating three times in a year for reasons that had nothing to do with their tolerance of the drug.

There is a second-order effect worth naming. Resuming with material from a different supplier compounds the uncertainty: the person is re-escalating and simultaneously changing the actual content of the vial. Reports from Janoshik, Medutest, PeptideMeter and VendorInvestigate consistently show that nominal strength and measured peptide content are not the same quantity, and a supplier change during a re-titration makes any symptom change uninterpretable. Change one variable at a time is a laboratory principle, and it applies here.

A dose is a number about a vial

Everything above assumes the dose administered is the dose intended. For licensed pens that assumption is reasonable. For research-grade lyophilised powder it is an assumption that should be examined, because a titration schedule built on an unreliable starting figure propagates the error through every subsequent rung.

Two distinct quantities are involved. Chromatographic purity describes the proportion of peptide-related material that is the intended peptide. Peptide content describes what fraction of the vial mass is peptide at all, the remainder being counter-ions, residual solvent, water and excipient. A vial can be ninety-nine per cent pure and contain substantially less peptide than its label states, and content is the figure that determines a dose.

Of the four independent services this market relies on, all report purity and only some report content routinely. Janoshik, Medutest, PeptideMeter and VendorInvestigate have each published results in which nominal and measured strength diverged. The Journal has argued in Analytics that content should be reported as standard, and we repeat it here for a titration-specific reason: without it, the arithmetic of a step is being performed on a number nobody has measured.

Non-standard concentrations and the errors they cause

Compounded and grey-market preparations are frequently supplied at concentrations that do not correspond to any licensed presentation. That is not in itself a quality problem, but it removes every mental shortcut a person may have acquired, and it interacts badly with escalation.

The recurring error is arithmetic rather than clinical: a person who has learned that a particular volume equals a particular dose changes vial, keeps the volume, and changes the dose without intending to. We have seen this reported in both directions and at magnitudes exceeding a full rung on the ladder.

Two habits protect against it. Recompute the volume-to-dose conversion whenever the vial changes, from the stated content and the reconstitution volume, rather than carrying the old figure forward. And write the result down somewhere attached to the vial, because the calculation is easy and the recall is not. The Journal covers the underlying arithmetic in the injection-practice file; the point here is that changing vials mid-titration converts a titration decision into a units problem, and units problems are where the largest errors in this field occur.

How the Journal reports dose figures

Three conventions govern the numbers in this file. Weight-change figures are quoted with the estimand named, because the treatment-policy and trial-product analyses in the obesity programmes differ by two to three percentage points and secondary coverage habitually mixes them. Doses are quoted as the weekly amount, not as a pen volume or a unit count, because volume and units depend on concentration and concentration varies. And where a figure derives from a responder analysis rather than a primary endpoint, we say so.

Where we describe practice rather than evidence, the text says so explicitly. A substantial part of what is known about titration in this class is craft knowledge held by clinicians, and reporting it is legitimate journalism. Presenting it as trial data is not.

Nothing in this file is medical advice. The Journal does not recommend doses, schedules, products or suppliers. Several compounds discussed here are sold for research use only and are not approved for human use in any jurisdiction. Decisions about treatment belong with a licensed clinician who has examined the person concerned.

One question is worth putting to the sponsors of the next generation of these molecules, and we intend to keep putting it. Escalation is the phase in which most discontinuation occurs, and discontinuation costs the entire treatment effect. A dose-escalation trial would be inexpensive relative to a cardiovascular outcome programme and would settle the most frequently asked practical question in the field. Nobody has run one.